Enoxaparin. A review of its clinical potential in the management of coronary artery disease.

Abstract:

UNLABELLED:Enoxaparin (enoxaparin sodium) is a low molecular weight heparin (LMWH) that is widely used in the prevention of deep venous thrombosis and pulmonary embolism in patients undergoing orthopaedic or general surgery. Its efficacy in these indications has led to study of its use in patients with coronary artery disease, particularly those with unstable angina, who have a high risk of myocardial infarction and death. A double-blind multicentre study [ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events)] showed that subcutaneous enoxaparin was more effective than intravenous unfractionated heparin (UFH) in reducing the incidence of the composite end-point of death, myocardial infarction or recurrent angina after 14 days in 3171 patients with recent-onset resting angina (i.e. unstable angina). There were no statistically significant between-group differences for the secondary end-point of death or myocardial infarction. Preliminary reports of long term follow-up data indicate that the clinical benefit of enoxaparin over UFH is maintained after 1 year. The only significant difference in tolerability between enoxaparin and UFH in ESSENCE was for minor haemorrhage (mostly injection-site ecchymosis), which was more common with the LMWH. Prospective pharmacoeconomic substudies of the ESSENCE trial suggest that total medical costs (including those for subsequent revascularisation procedures) for enoxaparin treatment are lower than those for UFH. The ESSENCE study is the first double-blind trial to show that a LMWH is more effective than UFH in patients with unstable angina. The superiority of enoxaparin was attributable mainly to its effects on recurrent angina. The level of anticoagulation achieved in the UFH group raises a number of issues which might have affected the apparent relative efficacy of enoxaparin and UFH. Preliminary data suggest that enoxaparin is at least as effective as UFH in reducing the incidence of subsequent cardiac events in patients receiving thrombolysis for acute myocardial infarction, and a randomised comparison with no additional treatment (other than aspirin) has demonstrated its efficacy in this indication. Enoxaparin has been ineffective in preventing restenosis after angioplasty CONCLUSIONS:The ESSENCE study has shown that enoxaparin is more effective than UFH in patients with unstable angina. Although clarification of some methodological issues would be beneficial, the available efficacy data, together with the practical advantages of LMWHs in general, suggest that enoxaparin is an effective and convenient means of treating unstable angina and should provide cost savings compared with UFH.

journal_name

Drugs

journal_title

Drugs

authors

Noble S,Spencer CM

doi

10.2165/00003495-199856020-00013

subject

Has Abstract

pub_date

1998-08-01 00:00:00

pages

259-72

issue

2

eissn

0012-6667

issn

1179-1950

journal_volume

56

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • The Multifactor Primary Prevention Trial in Göteborg, Sweden. Comparison with a previously untreated population sample.

    abstract::All male inhabitants of the city of Göteborg, who were born between 1915-1922 and 1924-1925 were included in the trial, and were 47 to 55 years of age on entry to the study in 1970 to 1973. One-third of these men were randomly allocated to an intervention group, whilst the other two-thirds acted as controls. Men of al...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198600311-00009

    authors: Wilhelmsen L,Berglund G,Elmfeldt D,Samuelsson O,Svardsudd K

    更新日期:1986-01-01 00:00:00

  • Treatment of Kaposi's sarcoma. Current guidelines and future perspectives.

    abstract::Kaposi's sarcoma is the most common malignancy associated with HIV infection, and the morbidity and mortality attributable to AIDS-related Kaposi's sarcoma (AIDS-KS) may be increasing. No curative therapy is available for AIDS-KS, but palliative therapy can eliminate or reduce cosmetically unacceptable lesions, reduce...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199448040-00006

    authors: Northfelt DW

    更新日期:1994-10-01 00:00:00

  • Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind.

    abstract::Non-24-h sleep-wake disorder (non-24) is a circadian rhythm disorder occurring in 55-70% of totally blind individuals (those lacking conscious light perception) in which the 24-h biological clock (central, hypothalamic, circadian pacemaker) is no longer synchronized, or entrained, to the 24-h day. Instead, the overt r...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0707-3

    authors: Emens JS,Eastman CI

    更新日期:2017-04-01 00:00:00

  • Hypopigmentary skin disorders: current treatment options and future directions.

    abstract::Alterations of skin and hair pigmentation are important features that have warranted treatment from ancient history on up to modern time. In some cultures, even today patients with vitiligo are regarded as social outcasts and are affected considerably both emotionally and physically. This article presents current opti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464010-00006

    authors: Hartmann A,Bröcker EB,Becker JC

    更新日期:2004-01-01 00:00:00

  • Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

    abstract::Certolizumab pegol (Cimzia(®)) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor (TNF)-α. The drug is indicated for subcutaneous use every 2 or 4 weeks (q2w or q4w) for the treatment of adults with mo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0009-3

    authors: Deeks ED

    更新日期:2013-01-01 00:00:00

  • Current use and future potential role of retinoids in dermatology.

    abstract::Since their introduction 15 years ago, retinoids have been increasingly used for topical and systemic treatment of psoriasis and other hyperkeratotic and parakeratotic skin disorders, keratotic genodermatoses, severe acne and acne-related dermatoses, and also for therapy and/or chemoprevention of skin cancer and other...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753030-00003

    authors: Orfanos CE,Zouboulis CC,Almond-Roesler B,Geilen CC

    更新日期:1997-03-01 00:00:00

  • The diuretic dilemma and the management of mild hypertension.

    abstract::Diuretics are used in first-step antihypertensive monotherapy or in combination with adrenergic-inhibiting agents in the majority of hypertensive patients in the United States. A 30-year experience has demonstrated that blood pressure is lowered to as great or greater a degree with diuretics than when many of the pres...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198600314-00007

    authors: Moser M

    更新日期:1986-01-01 00:00:00

  • Drug-induced hypertension: pathogenesis and management.

    abstract::Estrogenic compounds are the most important group of drugs that can induce hypertension. Studies have shown an incidence of significant hypertension amounting to less than 1% after 1 year of taking oral contraceptives and about 2% after 5 years. The ratio of the incidence of hypertension among ''takers'' to that of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197612030-00005

    authors: Stokes GS

    更新日期:1976-01-01 00:00:00

  • Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.

    abstract::When peripheral decarboxylation is blocked by carbidopa or benserazide, the main metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). Entacapone and tolcapone are new potent, selective and reversible nitrocatechol-type COMT inhibitors. Animal studies have demonstrated that entacapone ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059060-00004

    authors: Kaakkola S

    更新日期:2000-06-01 00:00:00

  • The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.

    abstract::Until recently, patients with advanced thyroid cancers had limited options for systemic treatment. With the introduction of tyrosine kinase inhibitors (TKIs) as a promising new class of targeted therapies for thyroid cancer, suddenly patients with advanced disease were given new options to extend survival. Guidelines ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-017-0733-1

    authors: Lirov R,Worden FP,Cohen MS

    更新日期:2017-05-01 00:00:00

  • Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

    abstract::Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs p...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767001-00005

    authors: Arca M

    更新日期:2007-01-01 00:00:00

  • [Properties and features of nabumetone].

    abstract::Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the 2,6-disubstituted naphthylalkanone class. It is a prodrug metabolised to an active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA), which preferentially inhibits cyclo-oxygenase-2 (COX-2) and has both anti-inflammatory and analgesic properties. The...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Davies NM,McLachlan AJ

    更新日期:2000-01-01 00:00:00

  • Cidofovir.

    abstract::Cidofovir is a nucleotide analogue which inhibits viral DNA polymerase and is effective against human cytomegalovirus (CMV) infection. It is phosphorylated to its active form by cellular enzymes. With the long intracellular half-life of its metabolites, cidofovir can be administered weekly during induction and every o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652020-00006

    authors: Lea AP,Bryson HM

    更新日期:1996-08-01 00:00:00

  • Colloid volume expanders. Problems, pitfalls and possibilities.

    abstract::Colloid solutions have been developed and used over the past 70 years as expanders of the intravascular space, based on an understanding of Starling's law. Increasing osmotic pressure with colloidal products has remained an attractive theoretical premise for volume resuscitation. Indeed, colloids have been shown to in...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855050-00002

    authors: Roberts JS,Bratton SL

    更新日期:1998-05-01 00:00:00

  • Glipizide: a review of its pharmacological properties and therapeutic use.

    abstract::Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide. It is rapidly metabolised to inactive metabolites whi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197918050-00001

    authors: Brogden RN,Heel RC,Pakes GE,Speight TM,Avery GS

    更新日期:1979-11-01 00:00:00

  • Grapefruit-drug interactions.

    abstract::Grapefruit juice and grapefruit product consumption have potential health benefits; however, their intake is also associated with interactions with certain drugs, including calcium channel blockers, immunosuppressants and antihistamines. The primary mechanism through which interactions are mediated is mechanism-based ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11585250-000000000-00000

    authors: Seden K,Dickinson L,Khoo S,Back D

    更新日期:2010-12-24 00:00:00

  • Brexpiprazole: First Global Approval.

    abstract::Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator that acts as a partial agonist of serotonin 1A (5-HT1A) and dopamine ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0462-2

    authors: Greig SL

    更新日期:2015-09-01 00:00:00

  • Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy.

    abstract::Oxatomide is an orally active H1-histamine receptor antagonist which, as appears to occur with some other antihistamines, also inhibits mast cell degranulation. Oxatomide has demonstrated response rates similar to those with other more established members of its drug class in a few studies of chronic urticaria and all...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198427030-00003

    authors: Richards DM,Brogden RN,Heel RC,Speight TM,Avery GS

    更新日期:1984-03-01 00:00:00

  • [Pain management: health economics and quality of life considerations].

    abstract::Pain represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to more than 60%, depending on the population. The impact of pain on economies is enormous, with the cost of back pain alone equivalent to more than one-fifth of one country's total health expenditure and 1....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Phillips CJ

    更新日期:2003-01-01 00:00:00

  • Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

    abstract::Iloprost is an analogue of epoprostenol (prostacyclin; PGI2; a potent but short-lived prostanoid mainly produced in the vascular endothelium) and mimics the pharmacodynamic properties of this compound, namely: inhibition of platelet aggregation, vasodilatation and, as yet ill-defined, cytoprotection. Improved metaboli...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243060-00008

    authors: Grant SM,Goa KL

    更新日期:1992-06-01 00:00:00

  • Torasemide. A review of its pharmacological properties and therapeutic potential.

    abstract::Torasemide (torsemide) is a high-ceiling loop diuretic which acts on the thick ascending limb of the loop of Henle to promote rapid and marked excretion of water, sodium and chloride. Like furosemide (frusemide), its major site of action is from the luminal side of the cell. Torasemide is at least twice as potent as f...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141010-00008

    authors: Friedel HA,Buckley MM

    更新日期:1991-01-01 00:00:00

  • Induction therapy in renal transplant recipients: how convincing is the current evidence?

    abstract::The goal of organ transplantation is to provide durable organ function while minimizing risks such as infection and cancer. Induction therapy in renal transplantation provides improved short- and long-term graft outcomes compared with placebo. Three agents are currently available and widely used in the US; rabbit anti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11631300-000000000-00000

    authors: Wagner SJ,Brennan DC

    更新日期:2012-03-26 00:00:00

  • Aggravation of ventricular arrhythmia. A drug-induced complication.

    abstract::Each antiarrhythmic agent can cause side effects, but most of these are easily recognised by the patient or physician. However, one potentially serious side effect common to all of these drugs is aggravation of ventricular arrhythmia. Often this is without symptoms and goes unrecognised by the patient. It occurs in 11...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500294-00009

    authors: Podrid PJ

    更新日期:1985-01-01 00:00:00

  • The relevance of serotonin antagonism in the treatment of hypertension.

    abstract::The role of serotonin in the pathogenesis of hypertension is not clear. Serotonin is produced by the enterochromaffin cells of the gut; the greater part of this is metabolised in the liver and lungs and nearly all of the remainder is taken up by the platelets. Consequently, circulating levels of serotonin are extremel...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198800361-00011

    authors: Doyle AE

    更新日期:1988-01-01 00:00:00

  • Drug treatment of stroke. Current status and future prospects.

    abstract::Despite advances in the understanding of the mechanism of cerebral injury during focal ischaemia, the best treatment of cerebral ischaemia is still prevention. The pathophysiological mechanisms that contribute to cerebral ischaemia are discussed relative to the many therapeutic interventions that have been attempted. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198835040-00005

    authors: Sila CA,Furlan AJ

    更新日期:1988-04-01 00:00:00

  • Tenapanor: First Approval.

    abstract::The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) [under the tradename IBSRELA®] and for hyperphosphataemia in patients with chronic kidney disease (CKD) on dialysis or with end stage re...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01215-9

    authors: Markham A

    更新日期:2019-11-01 00:00:00

  • The cost of treating systemic fungal infections.

    abstract::The increasing incidence of systemic fungal infections and rising medical costs have highlighted the need for an economic appraisal of antifungal agents to determine the most cost-effective therapeutic option. Cost savings derived from the prophylactic or empirical use of antifungal agents have been difficult to estim...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161001-00005

    authors: van Gool R

    更新日期:2001-01-01 00:00:00

  • Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.

    abstract::Recent developments in diagnosis and therapy of cytomegalovirus (CMV) infection have helped to reduce CMV-associated mortality following organ transplantation. However, CMV is still associated with significant morbidity in recipients of an allogeneic stem cell or solid-organ transplant. The clinical symptoms of active...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855010-00005

    authors: Hebart H,Kanz L,Jahn G,Einsele H

    更新日期:1998-01-01 00:00:00

  • Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome.

    abstract::Porcine-derived lung surfactant (PLS; Curosurf) has shown efficacy in neonatal respiratory distress syndrome. PLS consists of phospholipids, mainly dipalmitoylphosphatidylcholine, the primary surface-active agent of natural lung surfactant, and pulmonary surfactant-associated proteins which facilitate spreading and ad...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199448030-00006

    authors: Wiseman LR,Bryson HM

    更新日期:1994-09-01 00:00:00

  • Panobinostat: first global approval.

    abstract::Novartis has developed oral and intravenous formulations of panobinostat (Farydak(®)), a histone deacetylase (HDAC) inhibitor, for the treatment of cancer. HDACs have important roles in maintaining chromatin structure and in regulating gene expression, including that of tumour suppressor genes, and thus represent vali...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0388-8

    authors: Garnock-Jones KP

    更新日期:2015-04-01 00:00:00